Hydroxychloroquine in Coronavirus Disease 2019 Patients : What Still Needs to Be Known About the Kinetics
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 11 vom: 31. Dez., Seite 2962-2964 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martin-Blondel, Guillaume [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 06.01.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa558 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309754941 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309754941 | ||
| 003 | DE-627 | ||
| 005 | 20231225134619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa558 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309754941 | ||
| 035 | |a (NLM)32392332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martin-Blondel, Guillaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine in Coronavirus Disease 2019 Patients |b What Still Needs to Be Known About the Kinetics |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a dosage regimens | |
| 650 | 4 | |a drug monitoring | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a population pharmacokinetic modeling | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Ruiz, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Murris, Marlène |e verfasserin |4 aut | |
| 700 | 1 | |a Faguer, Stanilas |e verfasserin |4 aut | |
| 700 | 1 | |a Duhalde, Véronigue |e verfasserin |4 aut | |
| 700 | 1 | |a Eyvrard, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Izopet, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Mansuy, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Rolland, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Delavigne, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Guimbaud, Rosine |e verfasserin |4 aut | |
| 700 | 1 | |a Pugnet, Grégory |e verfasserin |4 aut | |
| 700 | 1 | |a Conil, Jean-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Georges, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Delobel, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Minville, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Silva Sifontes, Stein |e verfasserin |4 aut | |
| 700 | 1 | |a Concordet, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Gandia, Peggy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 11 vom: 31. Dez., Seite 2962-2964 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:11 |g day:31 |g month:12 |g pages:2962-2964 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa558 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 11 |b 31 |c 12 |h 2962-2964 | ||